Abu Syed Md Anisuzzaman | Oncology | Research Excellence Award

Published on by Global Scholar Awards

Dr. Abu Syed Md Anisuzzaman | Oncology | Research Excellence Award

Laboratory Molecular Technologist | Florida Cancer Specialists & Research Institute | United States

Dr. Abu Syed Md Anisuzzaman is a researcher affiliated with the University of Rajshahi, Bangladesh, specializing in pharmacology, molecular biology, and biomedical sciences. With 21 publications, 368 citations, and an h-index of 12, he has established a strong academic profile in cellular signaling, cancer biology, and therapeutic research. His work includes studies on apoptosis in cancer cells, oxidative stress, and intestinal epithelial function, contributing to advancements in drug discovery and disease mechanisms. Actively collaborating with international researchers, his research holds significant societal impact by supporting the development of novel therapeutic strategies, improving understanding of disease pathways, and advancing biomedical and pharmaceutical sciences globally.

Citation Metrics (Scopus)

368
275
180
90
0

Citations

368

Documents

21

h-index

12

Citations

Documents

h-index

View Scopus Profile
 View Google Scholar Profile
 View ORCID Profile

Featured Publications

Thomas Kipps | Oncology | Research Excellence Award

Published on by Global Scholar Awards

Dr. Thomas Kipps | Oncology | Research Excellence Award

Distinguished Professor | UC San Diego, Moores Cancer Center | United States

Dr. Thomas Kipps is a distinguished researcher at the University of California, San Diego, United States, specializing in oncology, hematology, and immunotherapy, with a particular focus on chronic lymphocytic leukemia (CLL). With an exceptional record of 518 publications, 69,084 citations, and an h-index of 122, he is a globally recognized leader in cancer research. His work has significantly advanced understanding of leukemia biology, targeted therapies, and clinical treatment strategies. Collaborating with an extensive international network, his research has directly influenced clinical practices and therapeutic development. Kipps’ contributions hold profound societal impact by improving patient outcomes, advancing precision medicine, and shaping modern cancer care worldwide.

Citation Metrics (Scopus)

69,084
50,000
35,000
15,000
0

Citations

69,084

Documents

518

h-index

122

Citations

Documents

h-index

View Scopus Profile
 View Google Scholar Profile
 View ORCID Profile

Featured Publications

Daulet Berikbol | Oncology | Scientific Advancement Achievement Award

Published on by Global Scholar Awards

Dr. Daulet Berikbol | Oncology | Scientific Advancement Achievement Award

UMIT International Oncology Center for Tomotherapy, LLP | Kazakhstan

Dr. Berikbol Daulet is a medical researcher at the UMIT International Oncological Center of Tomotherapy, Astana, Kazakhstan, with expertise in radiation oncology, tomotherapy, and advanced cancer treatment strategies. His research focuses on integrating precision radiotherapy with immunological and cellular therapies to improve outcomes in complex and advanced-stage cancers. He has authored 4 peer-reviewed publications, received 2 citations, and holds an h-index of 1, reflecting focused and emerging contributions to clinical oncology. Dr. Daulet actively engages in multidisciplinary clinical and translational research, contributing to collaborative studies that bridge radiotherapy and immunotherapy. His recent open-access case report on combined tomotherapy and autologous peripheral-blood–derived lymphocyte infusion for stage IIIa lung cancer highlights innovative, patient-centered treatment approaches, particularly for elderly patients. Through applied clinical research, he supports evidence-based oncology practice, advances modern cancer treatment technologies, and contributes to improved patient outcomes and broader societal benefit in healthcare.

Citation Metrics (Scopus)

4
3
2
1
0

Citations

2

Documents

4

h-index

1

Citations

Documents

h-index

View Scopus Profile View ORCID Profile

Featured Publications

Tae Il Kim | Oncology | Research Excellence Award

Published on by Global Scholar Awards

Prof. Tae Il Kim | Oncology | Research Excellence Award

Professor | Yonsei University College of Medicine | South Korea

Dr. Tae Il Kim is a distinguished researcher at Yonsei University College of Medicine in Seoul, South Korea, specializing in gastroenterology, colorectal cancer, and precision oncology. He has authored 337 Documents, which have received 8,659 citations, and holds an h-index of 46, reflecting his substantial global impact in biomedical and clinical research. Dr. Kim’s work focuses on translational and clinical studies that advance the understanding, diagnosis, and treatment of colorectal cancer and related gastrointestinal disorders. His notable contributions include elucidation of the HER2-ELF3-KRAS signaling axis in KRASG13D colorectal cancer, development of a novel risk score for 30-day adverse events following colonoscopy in older adults, and identification of circulating RNA biomarkers associated with the adenoma–carcinoma sequence. He has also pioneered multi-omic and machine learning-based approaches for precision oncology, including the CAN-Scan platform and non-invasive screening tools for early detection, as well as genome-wide association studies on nonhereditary colorectal polyposis and its recurrence. Dr. Kim collaborates extensively with over 800 co-authors across diverse disciplines and institutions, demonstrating a commitment to interdisciplinary and international research networks. His work has significantly contributed to improved patient care, early diagnosis, personalized therapeutic strategies, and the translation of scientific discoveries into clinical practice. By integrating innovation, rigorous research, and collaboration, Dr. Kim continues to shape the future of gastroenterology and oncology, enhancing global knowledge, advancing precision medicine, and elevating the visibility of Korean medical research on the international stage, with a tangible societal impact through better patient outcomes and public health advancements.

Profiles: Scopus | ORCID

Featured Publications

Kim, T. I., et al. (2025). Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes: Cellular and Molecular Biology. British Journal of Cancer. (Citations: 3)

Kim, T. I., et al. (2025). Circulating RNA markers associated with adenoma–carcinoma sequence in colorectal cancer. International Journal of Molecular Sciences. (Citations: 3)

Kim, T. I., et al. (2025). CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. Cell Reports Medicine. (Citations: 2)

Kim, T. I., et al. (2025). Machine learning-enabled non-invasive screening of tumor-associated circulating transcripts for early detection of colorectal cancer. International Journal of Molecular Sciences. (Citations: 2)

Kim, T. I., et al. (2025). Identification of genetic factors related with nonhereditary colorectal polyposis and its recurrence through genome-wide association study. Journal of Gastroenterology and Hepatology Australia.(Citations: 1)

Sara Mogedano Cruz | Oncology | Young Scientist Award

Published on by Global Scholar Awards

Mrs. Sara Mogedano Cruz | Oncology | Young Scientist Award

Universidad Europea de Madrid | Spain

Sara Mogedano-Cruz is a developing scholar in the field of biomedical and clinical sciences, affiliated with the Universidad Europea de Madrid in Villaviciosa de Odón, Spain, where she focuses on anatomical variability, anthropometric modeling, and evidence-based approaches to improving procedural safety. Her research emphasizes the integration of quantitative anatomical assessment into clinical workflows to enhance precision, reduce risk, and support safer invasive procedures. She has contributed to interdisciplinary studies that bridge anatomy, physiotherapy, clinical biomechanics, and medical engineering, strengthening the translation of scientific evidence into patient-centered practice. Her notable work includes the publication Predicting Median Nerve Depth from Anthropometric Features: A Tool for Safer Invasive Procedures, which examines how anthropometric predictors can guide clinicians in estimating nerve depth more accurately. Additionally, she co-authored the case report Percutaneous Peripheral Nerve Stimulation in Chemotherapy-Induced Neuropathy, reflecting her engagement with clinically meaningful interventions and her involvement in research that intersects neuromuscular assessment and oncology-related neuropathy. With five indexed documents and collaborations with national and international researchers, her scholarship is gaining visibility, supported by a growing citation record that underscores the relevance of her work to emerging clinical methodologies. Through her commitment to methodological rigor and multidisciplinary inquiry, she aims to advance innovations that connect anatomical science, clinical decision-making, and technological development for improved patient outcomes and broader societal benefit. Sara Mogedano-Cruz’s academic influence and research productivity are reflected in her metrics: 18 citations, 5 documents, and an h-index of 1.

Profiles: Scopus | ORCID

Featured Publication

1. Mogedano-Cruz, S., González-de-la-Flor, Á., Rodríguez-Anadón, C., Bohn, L., Villafañe, J., & Romero-Morales, C. (2025). Predicting median nerve depth from anthropometric features: A tool for safer invasive procedures. PLoS ONE, 20(8), e0330383. (Cited by: 1).

Vivek Kumar Garg | Breast Cancer | Best Researcher Award

Published on by Global Scholar Awards

Assoc. Prof. Dr. Vivek Kumar Garg | Breast Cancer | Best Researcher Award

Associate Professor | Rayat-Bahra University | India  

Assoc. Prof. Dr. Vivek Kumar Garg is an accomplished academic and researcher in the field of neurology and medical biochemistry, currently serving as Associate Professor at Rayat Bahra University, Mohali, with prior academic and research appointments at Chandigarh University, PGIMER Chandigarh, and the Institute of Genomics and Integrative Biology, New Delhi. He earned his Ph.D. in Neurology from PGIMER, Chandigarh, in 2018, focusing on the pharmacogenetics of antiepileptic drug-related adverse reactions in the North Indian population, following his M.Sc. in Medical Biochemistry (2008) and B.Sc. in Human Anatomy, Physiology, and Biochemistry (2006) from BFUHS, Faridkot. His professional experience spans teaching, research, and clinical diagnostics, including roles as Research Scientist in the COVID-19 laboratory at Punjab Biotechnology Incubator and as Demonstrator in Biochemistry at Government Medical College and Hospital, Chandigarh. His research interests include pharmacogenomics, neurodegenerative disorders, drug-induced adverse reactions, and biomarker discovery for complex diseases such as epilepsy, Alzheimer’s disease, and cancer. He is skilled in advanced research methodologies, including PCR, real-time PCR, ELISA, auto-analyzers, flame photometry, and biostatistical analysis, with strong expertise in both laboratory techniques and clinical research design. Dr. Garg has published extensively in peer-reviewed and indexed journals such as Human Immunology and Asian Journal of Psychiatry, and has also served as guest editor and editorial board member for international journals. He has guided multiple M.Sc. dissertations, delivered lectures, conducted workshops, and contributed as an examiner, BOS member, and research coordinator, reflecting his leadership in academia. His awards and honors include the prestigious ICMR Junior Research Fellowship, National Education Excellence Achievers Award, and multiple institutional recognitions as a transformative researcher and research luminary. With 1,757 citations, 90 documents, and an h-index of 18, Dr. Garg has established a strong academic footprint, reflecting both the impact of his research and his growing influence in biomedical sciences.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

  1. Kashyap, D., Garg, V. K., & Goel, N. (2021). Intrinsic and extrinsic pathways of apoptosis: Role in cancer development and prognosis. Advances in Protein Chemistry and Structural Biology, 125, 73–120. Cited by: 411

  2. Kashyap, D., Tuli, H. S., Yerer, M. B., Sharma, A., Sak, K., Srivastava, S., Pandey, A., … & Garg, V. K. (2021). Natural product-based nanoformulations for cancer therapy: Opportunities and challenges. Seminars in Cancer Biology, 69, 5–23. Cited by: 405

  3. Kashyap, D., Garg, V. K., Tuli, H. S., Yerer, M. B., Sak, K., Sharma, A. K., Kumar, M., … (2019). Fisetin and quercetin: Promising flavonoids with chemopreventive potential. Biomolecules, 9(5), 174. Cited by: 257

  4. Kashyap, D., Sharma, A., Tuli, H. S., Sak, K., Garg, V. K., Buttar, H. S., Setzer, W. N., … (2018). Apigenin: A natural bioactive flavone-type molecule with promising therapeutic function. Journal of Functional Foods, 48, 457–471. Cited by: 134

  5. Aggarwal, V., Kashyap, D., Sak, K., Tuli, H. S., Jain, A., Chaudhary, A., Garg, V. K., … (2019). Molecular mechanisms of action of tocotrienols in cancer: Recent trends and advancements. International Journal of Molecular Sciences, 20(3), 656. Cited by: 123

Boya Guan | Medical Oncology | Best Researcher Award

Published on by Global Scholar Awards

Prof. Boya Guan | Medical Oncology | Best Researcher Award

Pharmacist-in-charge​ at Tianjin Hospital | China

Boya Guan is a dedicated researcher and clinical pharmacist whose work bridges pharmacology, toxicology, and pharmaceutical sciences with a primary focus on osteosarcoma and bone cancer therapeutics. Over the course of her professional career, she has contributed significantly to oncology research by exploring drug mechanisms, drug resistance pathways, biomarker discovery, and clinical pharmacology applications. Her studies on triptolide-mediated ferroptosis and therapeutic strategies for overcoming drug resistance highlight her innovative approach to cancer research. Alongside her academic and clinical roles, she has been actively involved in translational projects that connect laboratory findings with patient care, ensuring that scientific discoveries lead to tangible clinical benefits. She has published in SCI-indexed journals, contributed to book chapters, and presented at national and international conferences, reflecting both the quality and impact of her work. With a strong commitment to research, innovation, and knowledge dissemination, she continues to shape advancements in oncology and pharmaceutical sciences.

Professional Profiles

Scopus Profile | ORCID Profile 

Education

Boya Guan has built a solid academic foundation that supports her extensive contributions to pharmaceutical research and clinical practice. She first pursued a degree in Pharmacy at Tianjin Medical University, where she developed a deep understanding of pharmacological principles and clinical applications. To expand her academic and professional horizons, she later completed a master’s program in Project and Operations Management at Southern New Hampshire University in the United States, equipping her with essential skills in management, leadership, and Six Sigma quality processes. This unique blend of pharmaceutical knowledge and operations management enabled her to approach research with a strategic and interdisciplinary perspective. She is currently advancing her expertise further by pursuing a master’s program in Pharmaceutical Analysis at Tianjin Medical University, focusing on advanced analytical methods and their role in clinical pharmacology. Her continuous academic development reflects her commitment to lifelong learning, professional growth, and scientific excellence in pharmaceutical sciences.

Experience

With over fourteen years of professional experience, Boya Guan has established herself as a highly skilled clinical pharmacist and researcher at Tianjin Hospital. In her role, she has been actively engaged in oncology-related pharmaceutical care, focusing on the mechanisms and efficacy of anticancer drugs while contributing to translational medicine initiatives. She has participated in significant clinical pharmacist training programs under the Tianjin Shortage Talent Program, where she deepened her expertise in oncology pharmacology and inpatient pharmaceutical care. Her experience is not limited to direct patient support; she has also been actively involved in clinical research, collaborating on projects that evaluate novel therapeutics such as denosumab for bone metastases and AI-based diagnostic tools. Beyond hospital-based responsibilities, she has presented her findings at conferences, published in peer-reviewed journals, and contributed book chapters, thereby extending her influence to both clinical and academic communities. Her experience reflects a balanced integration of research, practice, and innovation.

Research Interest

Boya Guan’s research interests lie at the intersection of oncology pharmacology, drug resistance mechanisms, and biomarker discovery, with a special focus on osteosarcoma therapeutics. She is particularly interested in investigating how targeted therapies and novel molecular pathways can overcome resistance to conventional drugs, thereby improving treatment outcomes for cancer patients. Her notable work includes exploring the role of triptolide in reversing cisplatin resistance through ferroptosis and lysosomal regulation, offering a promising therapeutic strategy. In addition to oncology, she is deeply engaged in analytical chemistry, employing dual-channel metabolomics and lipidomics approaches to identify biomarkers for diseases such as diabetes, thus contributing to early detection and precision medicine. She has also conducted systematic reviews and meta-analyses on VEGFR-TKIs in osteosarcoma, providing valuable evidence for clinical practice. Through her interdisciplinary approach, she aims to bridge pharmacology, translational research, and clinical application, ensuring her research has a meaningful and lasting impact on patient care.

Awards and Honors

Throughout her career, Boya Guan has earned recognition for her contributions to clinical pharmacy, research excellence, and innovative approaches to oncology therapeutics. She has been selected for prestigious programs such as the Tianjin Shortage Talent Program, which provided advanced clinical pharmacist training in oncology and inpatient care, underscoring her recognition as a promising specialist in pharmaceutical sciences. Her scientific contributions, including SCI-indexed journal publications, systematic reviews, and a book chapter on spinal metastases surgery, have also positioned her as a valuable contributor to academic and clinical communities. In addition to her professional achievements, she has been invited to present at multiple national and international conferences, where her research has been well received and acknowledged by peers. These honors reflect not only her strong academic and research background but also her potential to influence future directions in oncology and pharmaceutical research. Her growing recognition continues to strengthen her professional standing globally.

Research Skills

Boya Guan possesses a diverse range of research skills that combine laboratory expertise, clinical insight, and analytical methodologies. She is proficient in oncology pharmacology research, with specialized experience in studying drug resistance pathways, including ferroptosis-related mechanisms in osteosarcoma. Her analytical chemistry expertise includes metabolomics and lipidomics approaches for biomarker discovery, enabling her to contribute to the development of diagnostic and prognostic tools for complex diseases. She is skilled in conducting systematic reviews, meta-analyses, and clinical evaluations, ensuring evidence-based contributions to both research and practice. Additionally, she has demonstrated competence in designing and managing multidisciplinary research projects, including collaborations on AI-based diagnostic systems and drug efficacy studies. Her ability to translate laboratory findings into clinical strategies highlights her strength in bridging basic science with medical application. Coupled with strong writing, publication, and presentation skills, she is well-equipped to advance knowledge dissemination and foster innovation in oncology and pharmaceutical sciences.

Publication Top Notes

Title: Development of a dual-channel analytical approach for diabetic biomarker discovery in blood via integrative metabolomics and lipidomics
Year: 2025

Conclusion

Overall, Boya Guan is a highly deserving candidate for the Best Researcher Award. Her impactful contributions to osteosarcoma research, oncology pharmacology, biomarker discovery, and clinical drug evaluation showcase her ability to merge scientific innovation with real-world medical application. Her strong academic background, leadership in research, and commitment to improving cancer therapeutics reflect excellence in both scholarship and societal impact. With her continued focus on translational medicine and international collaborations, she holds significant potential to emerge as a global leader in oncology and pharmaceutical sciences.

Praveen Neeli | Oncology | Best Researcher Award

Published on by Global Scholar Awards

Dr. Praveen Neeli | Oncology | Best Researcher Award

Research Scientist at Moffitt Cancer Center | United States

Dr. Praveen Kumar Neeli is a passionate and innovative researcher in the fields of cancer biology, immunotherapy, and vaccine development. His research focuses on advancing therapeutic strategies such as CAR-T cell therapies, DNA-based vaccines, and immune checkpoint targeting for cancer and autoimmune diseases. Currently positioned at UT MD Anderson Cancer Center, he contributes to high-impact projects that bridge laboratory research with clinical applications, thereby influencing the future of oncology treatments. He has published extensively in top-tier journals, authored review articles, and contributed book chapters that highlight his deep scientific expertise. His patents and collaborations with industry underscore his ability to translate research findings into practical medical solutions. With over 520 citations and a growing h-index, Dr. Neeli’s work demonstrates significant scientific impact. He also holds editorial and reviewer roles in several reputed journals, further establishing his leadership and commitment to the global research community.

Professional Profiles

Google Scholar | Scopus Profile | ORCID Profile 

Education

Dr. Neeli holds a Ph.D. in Applied Biology with a specialization in cancer biology from the CSIR-Indian Institute of Chemical Technology, where he explored the molecular mechanisms of breast cancer progression by studying metadherin splice variants. His doctoral research laid the foundation for his later interest in cancer therapeutics. Prior to his Ph.D., he completed a Master’s degree in Genetics and a Bachelor’s degree in Biotechnology, Biochemistry, and Chemistry from Osmania University, which gave him strong grounding in biological sciences and laboratory practices. To complement his scientific expertise, he also pursued a Postgraduate Diploma in Patent Law from NALSAR University, which provides him a valuable perspective on intellectual property rights and translational research. This combination of academic credentials showcases both depth and breadth, reflecting a balance between advanced molecular biology and broader interdisciplinary skills, enabling him to contribute effectively to cutting-edge research and innovation in cancer biology and immunotherapy.

Experience

Dr. Neeli has built extensive research experience through progressive roles in prestigious institutions across India and the United States. At UT MD Anderson Cancer Center, he works as a postdoctoral fellow developing CAR-T therapies to address both cancer and autoimmune diseases, a project with transformative clinical potential. Prior to this, at Baylor College of Medicine, he was involved in designing DNA-based vaccines targeting cancers and infectious diseases, further strengthening his expertise in immunology and molecular therapeutics. Earlier in his career, he contributed to projects at CSIR-Centre for Cellular and Molecular Biology and Osmania University, focusing on molecular biology techniques such as cloning, expression, and purification of proteins. These experiences have enabled him to develop mastery in molecular biology, cell biology, immunological assays, and translational cancer research. Additionally, his editorial and reviewer roles, mentorship of students, and participation in international conferences demonstrate both his leadership and active engagement in the research community.

Research Interest

Dr. Neeli’s primary research interests lie in the development of innovative cancer immunotherapies and vaccines that can translate into effective clinical solutions. His current focus is on CAR-T cell therapies, aiming to engineer immune cells to specifically target cancer and autoimmune disease mechanisms. He is equally passionate about DNA-based vaccines and antibody engineering, particularly for their potential to treat hematological malignancies, breast cancer, and solid tumors. His work bridges molecular biology, immunology, and translational medicine, reflecting a comprehensive approach to therapeutic innovation. Additionally, he is interested in understanding tumor microenvironments, immune modulation, and mechanisms of drug resistance in cancer progression. The intersection of basic science and clinical application excites him, as it allows for the creation of therapies that directly benefit patients. He is also keen on exploring collaborative, multidisciplinary projects that integrate molecular biology with bioinformatics and clinical oncology to address unmet medical needs in cancer treatment.

Awards and Honors

Throughout his career, Dr. Neeli has been recognized with numerous awards and fellowships that highlight his academic and research excellence. He was awarded the ICMR Doctoral Research Fellowship, a highly competitive fellowship in India, which supported his Ph.D. work on breast cancer biology. His outstanding performance in national-level examinations such as GATE, CSIR-NET, and AP-SET further reflect his strong academic foundation and scientific aptitude. He has also actively participated in prestigious conferences including the American Association of Cancer Research (AACR) Annual Meeting, International Chemical Biology Society (ICBS), and other global research forums, showcasing his work to international audiences. His recognition extends beyond research fellowships to patents and technology development, with compounds licensed to pharmaceutical industries, which demonstrates the translational value of his contributions. These awards and achievements reflect not only his scientific excellence but also his commitment to bridging fundamental research with clinical and industrial applications.

Research Skills

Dr. Neeli possesses a diverse and advanced set of research skills spanning molecular biology, cell biology, immunology, and translational oncology. He is highly skilled in techniques such as cloning, gene expression, protein purification, site-directed mutagenesis, and chromatin immunoprecipitation. His expertise extends to advanced immunological methods, including ELISA, ELISPOT, flow cytometry, immune cell sorting, co-culture assays, and CAR-T cell engineering. He has significant experience in mammalian cell culture, confocal microscopy, and live imaging, as well as handling small animal models for preclinical studies. His work also involves bioinformatics tools for scientific analysis and visualization, combined with strong skills in scientific writing and communication. Additionally, his patents and translational projects highlight his capacity to move from bench research to industry-level applications. These skills collectively position him as a versatile and impactful researcher, capable of addressing complex biomedical challenges and contributing meaningfully to the advancement of cancer immunotherapy and vaccine development.

Publication Top Notes

Title: Metformin regulates mitochondrial biogenesis and senescence through AMPK mediated H3K79 methylation: Relevance in age-associated vascular dysfunction
Authors: S. Karnewar, P.K. Neeli, D. Panuganti, S. Kotagiri, S. Mallappa, N. Jain, et al.
Year: 2018
Citation: 147

Title: The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects
Authors: B. Lu, J.M. Lim, B. Yu, S. Song, P. Neeli, N. Sobhani, P.K., S.R. Bonam, et al.
Year: 2024
Citation: 95

Title: Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
Authors: N. Sobhani, B. Scaggiante, R. Morris, D. Chai, M. Catalano, D.R. Tardiel-Cyril, P. Neeli, et al.
Year: 2022
Citation: 77

Title: AR-V7 in metastatic prostate cancer: a strategy beyond redemption
Authors: N. Sobhani, P.K. Neeli, A. D’Angelo, M. Pittacolo, M. Sirico, I.C. Galli, et al.
Year: 2021
Citation: 64

Title: AMPK inhibits MTDH expression via GSK 3β and SIRT 1 activation: potential role in triple negative breast cancer cell proliferation
Authors: P.N. Gollavilli, A.K. Kanugula, R. Koyyada, S. Karnewar, P.K. Neeli, et al.
Year: 2015
Citation: 59

Title: A novel metadherinΔ7 splice variant enhances triple negative breast cancer aggressiveness by modulating mitochondrial function via NFĸB-SIRT3 axis
Authors: P.K. Neeli, P.N. Gollavilli, S. Mallappa, S.G. Hari, S. Kotamraju
Year: 2020
Citation: 41

Title: Mitochondria-targeted esculetin mitigates atherosclerosis in the setting of aging via the modulation of SIRT1-mediated vascular cell senescence and mitochondrial function
Authors: S. Karnewar, S. Pulipaka, S. Katta, D. Panuganti, P.K. Neeli, R. Thennati, et al.
Year: 2022
Citation: 37

Title: Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization
Authors: S. Mallappa, P.K. Neeli, S. Karnewar, S. Kotamraju
Year: 2019
Citation: 35

Title: Expanding anti-CD38 immunotherapy for lymphoid malignancies
Authors: M.Z.Y.L., X. Wang, X. Yu, W. Li, P. Neeli, M. Liu, L. Li
Year: 2022
Citation: 31

Title: p53 antibodies as a diagnostic marker for cancer: A meta-analysis
Authors: N. Sobhani, G. Roviello, A. D’Angelo, R. Roudi, P.K. Neeli, D. Generali
Year: 2021
Citation: 22

Title: DOT1L regulates MTDH mediated angiogenesis in triple-negative breast cancer: Intermediacy of NF-κB-HIF1α axis
Authors: P.K. Neeli, S. Sahoo, S. Karnewar, G. Singuru, S. Pulipaka, S. Annamaneni, et al.
Year: 2022
Citation: 16

Title: AI-powered discovery of a novel p53-Y220C reactivator
Authors: Y. Li, S. Zhou, D. Chai, X. Wang, P. Neeli, X. Yu, A. Davtyan, K. Young
Year: 2023
Citation: 11

Conclusion

Dr. Praveen Kumar Neeli is a highly deserving candidate for the Best Researcher Award. His cutting-edge research in CAR-T therapies, DNA vaccines, and cancer biology demonstrates both scientific depth and translational impact. With multiple high-impact publications, patents, international collaborations, and community contributions, he stands out as a researcher who not only advances knowledge but also contributes meaningfully to clinical applications and society. His growing leadership roles, strong academic foundation, and ongoing projects position him as a promising future leader in oncology and immunotherapy research.

William Skelton | Medical Oncology | Best Researcher Award

Published on by Global Scholar Awards

Dr. William Skelton | Medical Oncology | Best Researcher Award

Assistant Professor of Medicine at University of Virginia Comprehensive Cancer Center, United States

Dr. William Paul Skelton IV is an Assistant Professor of Medicine at the University of Virginia School of Medicine, specializing in Hematology and Oncology. With extensive training from prestigious institutions like Moffitt Cancer Center and the University of Florida, Dr. Skelton is a dedicated clinician and researcher in Genitourinary Oncology. His career is marked by numerous awards, including recognition for excellence in patient care and teaching. Dr. Skelton is committed to advancing cancer treatment through research and has a notable record of impactful publications and presentations in the field. His professional contributions extend to mentoring and serving on various academic committees.

Publication Profile

Education

Dr. William Paul Skelton IV completed his Hematology/Oncology Fellowship at Moffitt Cancer Center, University of South Florida, followed by a Chief Medical Residency at the University of Florida. He earned his Internal Medicine Residency from the same institution and graduated with honors in research from the University of Florida College of Medicine. Dr. Skelton holds a Magna Cum Laude degree in Chemistry from Duke University and a high school diploma with exceptional achievements from King International Baccalaureate High School.

Experience

Dr. Skelton’s professional journey includes his current role as an Assistant Professor of Medicine at the University of Virginia School of Medicine. Previously, he served as a Hematology/Oncology Fellow at Moffitt Cancer Center and as a Chief Medical Resident during his Internal Medicine Residency at the University of Florida. His clinical expertise encompasses Genitourinary Oncology, and he has contributed significantly to medical education through precepting and mentoring medical students, residents, and fellows.

Awards and Honors

Dr. Skelton has received several prestigious awards, including the Moffitt Cancer Center SPOTTED in FellowSHIP patient care Recognition Award in both 2020 and 2021. He was honored with the Florida ACP Chief Resident Award and the UF Senior Resident Medical Student Teaching Award. Additional accolades include the Craig S. Kitchens Outstanding Senior Medicine Resident Award and selection into the Alpha Omega Alpha Honor Society. His academic honors also include Phi Beta Kappa and the Merck Index Award.

Research Focus

Dr. Skelton’s research primarily focuses on Genitourinary Oncology, particularly the therapeutic advancements and molecular mechanisms underlying renal and bladder cancers. His work includes investigating predictive tools for advanced renal cancer and exploring the impact of systemic therapies on cancer progression. Dr. Skelton’s research is aimed at improving patient outcomes through innovative treatment strategies and clinical trials.

Publications Top Notes

  • Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
    • Authors: Skelton, W.P., Masur, J., Thomas, J., Jain, R.K., Sonpavde, G.P.
    • Journal: Clinical Genitourinary Cancer
    • Year: 2024
    • Citations: 0 💊💉🩺
  • Impact of DPP4 Inhibition on Survival in Patients With Metastatic Renal Cell Carcinoma and Type 2 Diabetes Mellitus
    • Authors: Ali, S., Fortune, K., Masur, J., Dreicer, R., Skelton, W.P.
    • Journal: Clinical Genitourinary Cancer
    • Year: 2024
    • Citations: 0 🩸👨‍⚕️🧬
  • Impact of Institutional Universal Microsatellite-Instability (MSI) Reflex Testing on Molecular Profiling Differences Between Younger and Older Patients with Colorectal Cancer
    • Authors: Altshuler, E., Franke, A.J., Skelton, W.P., Dai, Y., George, T.J.
    • Journal: Clinical Colorectal Cancer
    • Year: 2023
    • Citations: 2 🧬🔬
  • Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma
    • Authors: Zhang, Y., Kumar, P., Adashek, J.J., Manley, B.J., Spiess, P.E.
    • Journal: Cells
    • Year: 2022
    • Citations: 6 🧫🔬💊
  • FGFR2/3 Genomic Alterations and Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
    • Authors: Adib, E., El-Zarif, T., Jain, R.K., Choueiri, T.K., Sonpavde, G.P.
    • Journal: BJUI Compass
    • Year: 2022
    • Citations: 6 🧬💉🧪
  • Clinical Cases Debate: Neoadjuvant Versus Adjuvant Immunotherapy in Localized Renal Cell Carcinoma (RCC)
    • Authors: Skelton, W.P., Dahmen, A., Chatwal, M., Chahoud, J., Spiess, P.E.
    • Book Chapter: Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers
    • Year: 2022
    • Citations: 0 📖🦠💉
  • Optimal Pathological Response After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Results from a Global, Multicentre Collaboration
    • Authors: Ravi, P., Pond, G.R., Diamantopoulos, L.N., Grivas, P., Sonpavde, G.P.
    • Journal: BJU International
    • Year: 2021
    • Citations: 13 🧬🌍
  • Systematic Analysis of Extracting Data on Advance Directives from Patient Electronic Health Records (EHR) in Terminal Oncology Patients
    • Authors: Starr, J.S., Skelton, W.P., Rahmanian, K.P., George, T.J., Moseley, R.E.
    • Journal: Journal of Palliative Care
    • Year: 2021
    • Citations: 0 📊🩺📋
  • A Comprehensive Review of Randomized Clinical Trials Shaping the Landscape of Rectal Cancer Therapy
    • Authors: Franke, A.J., Skelton, W.P., George, T.J., Iqbal, A.
    • Journal: Clinical Colorectal Cancer
    • Year: 2021
    • Citations: 4 🧪📊
  • Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?
    • Authors: Adashek, J.J., Zhang, Y., Skelton, W.P., Manley, B., Spiess, P.E.
    • Journal: Frontiers in Oncology
    • Year: 2021
    • Citations: 5 🧬🩺💉